Human BAFF/BLyS/TNFSF13B Antibody

Catalog #: MAB124
6 Citations Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
MAB124-SP
MAB124-500
MAB124-100

Save 15% on Select RUO Reagents. See Details.

Cell Proliferation Induced by BAFF/BLyS/TNFSF13B and Neutralization by Human BAFF/BLyS/TNFSF13B Antibody.

1 Image

Product Details

Citations (6)

Supplemental Products

Reviews

Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human BAFF/BLyS/TNFSF13B Antibody Summary

Species Reactivity

Human

Specificity

Detects human BAFF in direct ELISAs.

Source

Monoclonal Mouse IgG_2B Clone # 148725

Purification

Protein A or G purified from hybridoma culture supernatant

Immunogen

Mouse myeloma cell line NS0-derived recombinant human BAFF
Ala134-Leu285
Accession # Q9Y275

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Label

Unconjugated

Applications

Recommended Concentration

Sample

Neutralization

Measured by its ability to neutralize BAFF/BLyS/TNFSF13B-induced proliferation in mouse B cells. At 20 µg/mL, this anti-BAFF/BLyS/TNFSF13B antibody will neutralize > 60% of 5 ng/mL Recombinant Human BAFF/BLyS/TNFSF13B-induced proliferation of mouse B cells.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Neutralization

View Larger

Cell Proliferation Induced by BAFF/BLyS/TNFSF13B and Neutralization by Human BAFF/BLyS/TNFSF13B Antibody. Recombinant Human BAFF/BLyS/TNFSF13B (Catalog # 2149-BF) stimulates proliferation in mouse B cells in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Human BAFF/BLyS/TNFSF13B (5 ng/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human BAFF/BLyS/TNFSF13B Monoclonal Antibody (Catalog # MAB124). At 20 µg/mL, this anti-BAFF/BLyS/TNFSF13B antibody will neutralize >60% of Recombinant Human BAFF/BLyS/TNFSF13B-induced proliferation of mouse B cells.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: BAFF/BLyS/TNFSF13B

BAFF, also known as B-lymphocyte stimulator (BLyS), TNF- and APOL-related leukocyte expressed ligand 1 (TALL-1), and TNF homolog that activates apoptosis, NFKB and JNK (THANK), is a TNF ligand superfamily member and has been designated TNFSF13B.

Long Name

B cell Activating Factor

Entrez Gene IDs

10673 (Human); 24099 (Mouse); 498666 (Rat); 102123214 (Cynomolgus Monkey)

Alternate Names

ApoL related ligand TALL-1; B lymphocyte stimulator; BAFF; BAFFB-cell activating factor; B-cell-activating factor; BLyS; BLYSB-lymphocyte stimulator; CD257 antigen; CD257; Dendritic cell-derived TNF-like molecule; DTL; TALL1; TALL-1delta BAFF; TALL1Delta4 BAFF; THANK; TNF- and APOL-related leukocyte expressed ligand 1; TNF and ApoL-related leukocyte expressed ligand 1; TNF homolog that activates apoptosis; TNFSF13B; TNFSF20; tumor necrosis factor (ligand) superfamily, member 13b; tumor necrosis factor (ligand) superfamily, member 20; tumor necrosis factor ligand superfamily member 13B; tumor necrosis factor superfamily, member 13b; tumor necrosis factor-like protein ZTNF4; ZTNF4

Product Datasheets

Product Datasheet

COA

SDS

Related Research Areas

Citations for Human BAFF/BLyS/TNFSF13B Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

6 Citations: Showing 1 - 6
Filter your results:

Filter by:

Human central nervous system astrocytes support survival and activation of B cells: implications for MS pathogenesis
Authors: H Touil, A Kobert, N Lebeurrier, A Rieger, P Saikali, C Lambert, L Fawaz, CS Moore, A Prat, J Gommerman, JP Antel, Y Itoyama, I Nakashima, A Bar-Or
J Neuroinflammation, 2018-04-19;15(1):114.
Species: Human
Sample Types: Whole Cells
Applications: Neutralization
Endotoxemia contributes to CD27+ memory B-cell apoptosis via enhanced sensitivity to Fas ligation in patients with Cirrhosis
Sci Rep, 2016-11-18;6(0):36862.
Species: Human
Sample Types: Whole Cells
Applications: Neutralization
IFN-beta therapy modulates B-cell and monocyte crosstalk via TLR7 in multiple sclerosis patients.
Authors: Giacomini E, Severa M, Rizzo F, Mechelli R, Annibali V, Ristori G, Riccieri V, Salvetti M, Coccia E
Eur J Immunol, 2013-05-28;43(7):1963-72.
Species: Human
Sample Types: Whole Cells
Applications: Neutralization
IL-15 Expression on RA Synovial Fibroblasts Promotes B Cell Survival.
Authors: Benito-Miguel M, Garcia-Carmona Y, Balsa A, Bautista-Caro MB, Arroyo-Villa I, Cobo-Ibanez T, Bonilla-Hernan MG, De Ayala CP, Sanchez-Mateos P, Martin-Mola E, Miranda-Carus ME
PLoS ONE, 2012-07-09;7(7):e40620.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry, Neutralization
Constitutive NF-kappaB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas.
Authors: Fu L, Lin-Lee YC, Pham LV, Tamayo A, Yoshimura L, Ford RJ
Blood, 2006-02-23;107(11):4540-8.
Species: Human
Sample Types: Whole Cells
Applications: ICC
Dok-7 regulates neuromuscular synapse formation by recruiting Crk and Crk-L.
Authors: Hallock PT, Xu CF, Park TJ
Genes Dev., 2010-11-01;24(21):2451-61.